Paroxysmal Nocturnal Haemoglobinuria (PNH) Pipeline Analysis 2019 (H1)

Report
84 Pages
May 2019
Region: Global
Knowledge Sourcing Intelligence LLP
ID: 4801801

Paroxysmal Nocturnal Haemoglobinuria (PNH) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.

Paroxysmal Nocturnal Haemoglobinuria (PNH) Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Paroxysmal Nocturnal Haemoglobinuria (PNH) is a rare acquired life-threatening blood disorder. The disease is caused by the mutation of a PIG-A gene which occurs in the bone marrow stem cell. The disease causes the destruction of red blood cells, blood clots and impairs the bone marrow function.

The report provides Paroxysmal Nocturnal Haemoglobinuria (PNH) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.

Major industry players profiled as part of the report are Novartis AG, Achillion Pharmaceuticals, Inc., AKARI Therapeutics and F. Hoffmann-La Roche Ltd. among others.

Scope:

By Company
By Phase
By Molecule Type
By Region
By Route of Administration

1. Introduction

1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region

2. Disease Overview

2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics

4.1. Drivers
4.2. Restraints
4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling

Drug Name
Generic Name
Synonyms
Company
Collaborator
Route of administration
Target
Mechanism of Action
Technology
Molecule type
CAS Number
Weight
Chemical Formula
IUPAC name
ATC code

5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region

6. Company profiling

6.1. Achillion Pharmaceuticals, Inc.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Novartis AG
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. AKARI Therapeutics
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. F. Hoffmann-La Roche Ltd.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Alnylam Pharmaceuticals, Inc.
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Apellis Pharmaceuticals
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Ra Pharmaceuticals, Inc.
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Amyndas Pharmaceuticals
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Alexion
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Chugai Pharmaceutical Co., Ltd.
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. ISU ABXIS
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. NovelMed Inc.
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Omeros Corporation
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. Regeneron Pharmaceuticals, Inc.
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Aurin Biotech Inc.
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. Amgen Inc.
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT

Companies Mentioned

Achillion Pharmaceuticals, Inc.
Novartis AG
AKARI Therapeutics
F. Hoffmann-La Roche Ltd.
Alnylam Pharmaceuticals, Inc.
Apellis Pharmaceuticals
Ra Pharmaceuticals, Inc.
Amyndas Pharmaceuticals
Alexion
Chugai Pharmaceutical Co., Ltd.
ISU ABXIS
NovelMed Inc.
Omeros Corporation
Regeneron Pharmaceuticals, Inc.
Aurin Biotech Inc.
Amgen Inc.

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2794EUR$2,900USD£2,404GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€5685EUR$5,900USD£4,890GBP

Table of Contents

Companies Mentioned

Methodology

Related Topics

Related Reports

Paroxysmal Hemoglobinuria - Pipeline Insight, 2024

Paroxysmal Nocturnal Haemoglobinuria - Pipeline Insight, 2024

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report

Paroxysmal Nocturnal Hemoglobinuria Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2024